miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression

Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex

(2014) Deshui Jia et al.   HEPATOLOGY

microRNAs miR-27a and miR-27b Directly Regulate Liver Dihydropyrimidine Dehydrogenase Expression through Two Conserved Binding Sites

(2014) S. M. Offer et al.   MOLECULAR CANCER THERAPEUTICS

MicroRNAs as therapeutic targets in chemoresistance

(2013) Michela Garofalo et al.   DRUG RESISTANCE UPDATES

Genome-wide screening reveals that miR-195 targets the TNF-α/NF-κB pathway by down-regulating IκB kinase alpha and TAB3 in hepatocellular carcinoma

(2013) Jie Ding et al.   HEPATOLOGY

Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways

(2013) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrated molecular analysis of clear-cell renal cell carcinoma

(2013) Yusuke Sato et al.   NATURE GENETICS

MicroRNAs and other non-coding RNAs as targets for anticancer drug development

(2013) Hui Ling et al.   NATURE REVIEWS DRUG DISCOVERY

Technologies for deriving primary tumor cells for use in personalized cancer therapy

(2013) Abhisek Mitra et al.   TRENDS IN BIOTECHNOLOGY

MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

(2012) Sidong Huang et al.   CELL

Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems

(2012) Oktay Tacar et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)

(2012) Joong-Won Park et al.   LIVER INTERNATIONAL

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Combinatorial drug therapy for cancer in the post-genomic era

(2012) Bissan Al-Lazikani et al.   NATURE BIOTECHNOLOGY

miR-34 – a microRNA replacement therapy is headed to the clinic

(2012) Andreas G. Bader   Frontiers in Genetics

Simultaneous Delivery of siRNA and Paclitaxel via a “Two-in-One” Micelleplex Promotes Synergistic Tumor Suppression

(2011) Tian-Meng Sun et al.   ACS Nano

An HNF4α-miRNA Inflammatory Feedback Circuit Regulates Hepatocellular Oncogenesis

(2011) Maria Hatziapostolou et al.   CELL

Cancer genomics: from discovery science to personalized medicine

(2011) Lynda Chin et al.   NATURE MEDICINE

MicroRNA pharmacogenomics: Post-transcriptional regulation of drug response

(2011) Jakob Lewin Rukov et al.   TRENDS IN MOLECULAR MEDICINE

MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells

(2010) Francesca Fornari et al.   CANCER RESEARCH

Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion

(2010) Pei-Jer Chen et al.   LIVER INTERNATIONAL

Towards a knowledge-based Human Protein Atlas

(2010) Mathias Uhlen et al.   NATURE BIOTECHNOLOGY

Targeting microRNAs in cancer: rationale, strategies and challenges

(2010) Ramiro Garzon et al.   NATURE REVIEWS DRUG DISCOVERY

Correlations between RNA and protein expression profiles in 23 human cell lines

(2009) Marcus Gry et al.   BMC GENOMICS

miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation

(2009) Michela Garofalo et al.   CANCER CELL

MicroRNAs: Target Recognition and Regulatory Functions

(2009) David P. Bartel   CELL

Statistical methods for analysis of high-throughput RNA interference screens

(2009) Amanda Birmingham et al.   NATURE METHODS

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

(2008) Alberto F. Sobrero et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials

(2008) Pippa Newell et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE